DDX41 and acute myeloid leukemia: Moreover, DDX41 mutations appear to be associated with favorable prognosis when AML is treated with HMA plus venetoclax according to ELN2024 [121]; however, this observation is based on a limited number of patients [159,160], making these findings preliminary.